Overall, we identified four therapeutic targets that could be beneficial to target in combination with antibiotic therapy to decrease the activation of Thrombosis (Fig. 3C), in which three of them were already identified in mono-therapy evaluation, i.e. IFN-γ, sTNF-R or TF, but blocking them could almost deactivate Thrombosis when combined with antibiotics. This evidence concerns the gene IFNG and Venous thrombosis.